BPTH
BIO-PATH HOLDINGS, INC.
- PER (TTM)
- -
- PER (Forward)
- -0.01
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- -0.06
- 시가총액
- 467,107
- 배당수익률
- -
- 베타
- -0.28
- 1개월 수익률
- -16.67%
- 3개월 수익률
- -16.67%
- 6개월 수익률
- -44.44%
- 1년 수익률
- -72.22%
- 2년 수익률
- -
- 5일 평균거래량
- 17940
- 60일 평균거래량
- 13665
- 1년 평균거래량
- 35050
- 5d/60d 거래량 비율
- 1.31×
- 60d/1y 거래량 비율
- 0.39×
- 변동성(60일, 연환산)
- 138.69%
- BB 스퀴즈 스코어
- 0.61
- SMA50 비율
- 0.82
- SMA200 비율
- 0.64
- RSI (14)
- 34
- 20일 수렴도
- 0.06
- 52주 최고
- 0.22
- 52주 최저
- 0.05
- 고점 대비
- -77.27%
- 저점 대비
- 0.00%
펀더멘털 갱신: 2026-05-10T08:04:29+00:00 · 시세 갱신: 2026-05-10T06:14:18+00:00
회사 정보
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.